GAMMA Investing LLC Reduces Stock Holdings in Chemed Corporation $CHE

GAMMA Investing LLC decreased its holdings in shares of Chemed Corporation (NYSE:CHE) by 13.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 235 shares of the company’s stock after selling 36 shares during the quarter. GAMMA Investing LLC’s holdings in Chemed were worth $114,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of CHE. Whipplewood Advisors LLC increased its holdings in Chemed by 54.5% in the 1st quarter. Whipplewood Advisors LLC now owns 51 shares of the company’s stock valued at $31,000 after purchasing an additional 18 shares during the last quarter. Renasant Bank boosted its holdings in Chemed by 2.3% during the 1st quarter. Renasant Bank now owns 815 shares of the company’s stock valued at $501,000 after acquiring an additional 18 shares during the period. Impact Capital Partners LLC grew its position in Chemed by 2.7% in the 1st quarter. Impact Capital Partners LLC now owns 763 shares of the company’s stock valued at $469,000 after acquiring an additional 20 shares in the last quarter. Cim LLC increased its stake in Chemed by 1.0% during the first quarter. Cim LLC now owns 2,029 shares of the company’s stock worth $1,248,000 after purchasing an additional 21 shares during the period. Finally, KFG Wealth Management LLC boosted its stake in shares of Chemed by 4.6% in the first quarter. KFG Wealth Management LLC now owns 525 shares of the company’s stock valued at $323,000 after purchasing an additional 23 shares during the period. Institutional investors and hedge funds own 95.85% of the company’s stock.

Insider Buying and Selling at Chemed

In other news, CEO Kevin J. Mcnamara sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $461.28, for a total transaction of $1,383,840.00. Following the completion of the sale, the chief executive officer directly owned 96,197 shares in the company, valued at $44,373,752.16. This trade represents a 3.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Patrick P. Grace sold 150 shares of the stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $463.39, for a total value of $69,508.50. Following the transaction, the director owned 3,397 shares of the company’s stock, valued at approximately $1,574,135.83. This trade represents a 4.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 13,162 shares of company stock valued at $5,677,511 in the last ninety days. Corporate insiders own 3.29% of the company’s stock.

Wall Street Analysts Forecast Growth

CHE has been the subject of a number of recent research reports. Wall Street Zen lowered Chemed from a “buy” rating to a “hold” rating in a report on Saturday, July 5th. Bank of America decreased their price target on shares of Chemed from $610.00 to $595.00 and set a “buy” rating for the company in a research note on Wednesday, September 10th. Oppenheimer dropped their price objective on shares of Chemed from $650.00 to $580.00 and set an “outperform” rating on the stock in a research report on Thursday, July 31st. Royal Bank Of Canada dropped their target price on Chemed from $640.00 to $589.00 and set an “outperform” rating on the stock in a report on Thursday, July 31st. Finally, Jefferies Financial Group raised Chemed from a “hold” rating to a “buy” rating and lifted their price target for the stock from $490.00 to $550.00 in a report on Tuesday, September 2nd. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $578.50.

Chemed Price Performance

Shares of CHE opened at $440.06 on Thursday. Chemed Corporation has a 1-year low of $408.42 and a 1-year high of $623.60. The stock has a market cap of $6.41 billion, a price-to-earnings ratio of 22.63, a price-to-earnings-growth ratio of 2.61 and a beta of 0.43. The firm has a 50 day simple moving average of $449.68 and a 200-day simple moving average of $518.69.

Chemed (NYSE:CHE) last released its quarterly earnings results on Tuesday, July 29th. The company reported $4.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.02 by ($1.75). The firm had revenue of $618.80 million for the quarter, compared to analyst estimates of $650.60 million. Chemed had a return on equity of 25.83% and a net margin of 11.56%.Chemed’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same period in the prior year, the business earned $5.47 earnings per share. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. On average, equities analysts expect that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.

Chemed Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 29th. Investors of record on Monday, August 11th were issued a $0.60 dividend. The ex-dividend date was Monday, August 11th. This is a positive change from Chemed’s previous quarterly dividend of $0.50. This represents a $2.40 annualized dividend and a yield of 0.5%. Chemed’s payout ratio is 12.34%.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.